Parkinson's disease articles from across Nature Portfolio

The treatment of Parkinson’s disease (PD) is hampered by the lack of effective blood–brain barrier (BBB) traversing drugs. Here, the authors report nanozyme-integrated metal-organic frameworks with antioxidant activity and chiral-dependent BBB transendocytosis as anti-neuroinflammatory agents for PD treatment.

This Perspective proposes a tripartite model involving the amygdala, hippocampus and striatum as key structures underlying cognitive dysfunction in Parkinson disease. The authors explore the anatomical and functional relationships of the structures and summarize evidence of their involvement in the cognitive aspects of the disease.

The differentiation of human pluripotent stem cells into dopaminergic neurons is challenging. Here, the authors developed lineage-restricted undifferentiated stem cells, which have an enhanced ability for differentiating into dopaminergic neurons.

New research indicates that in a mouse model of Parkinson disease, α-synuclein is trafficked from the brain to the gut by CD11c-expressing macrophages.

In a plenary lecture at the XXVI World Congress of Neurology, Anthony Lang presented a new biological classification model for Parkinson disease.

Epidural electrical stimulation of the spinal cord alleviated freezing-of-gait and other postural impairments in a patient with Parkinson’s disease, potentially addressing an unmet need and offering an exciting new avenue for therapy.

Electrical stimulation improved his mobility, although researchers say that a larger study is needed to assess the device.